| 2019 | 2018 |
| Deferred tax assets | | |
| Non-capital loss carryforwards | $161,119 | $129,436 |
| Capital loss carryforwards | 155 | 417 |
| Undeducted scientific research and development expenses | 137,253 | 123,114 |
| Depreciation and amortization | 683,777 | 829,369 |
| Restructuring costs and other reserves | 17,845 | 17,202 |
| Deferred revenue | 53,254 | 62,726 |
| Other | 59,584 | 57,461 |
| Total deferred tax asset | $1,112,987 | $1,219,725 |
| Valuation Allowance | $(77,328) | $(80,924) |
| Deferred tax liabilities | | |
| Scientific research and development tax credits | $(14,482) | $(13,342) |
| Other | (72,599) | (82,668) |
| Deferred tax liabilities | $(87,081) | $(96,010) |
| Net deferred tax asset | $948,578 | $1,042,791 |
| Comprised of: | | |
| Long-term assets | 1,004,450 | 1,122,729 |
| Long-term liabilities | (55,872) | (79,938) |
| $948,578 | $1,042,791 |